share_log

Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.

Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.

Marker Therapeutics的股票正在下跌。该公司报告了其针对复发性淋巴瘤的1期APOLLO研究中Mt-601的结果。
Benzinga ·  12/19 05:57

Marker Therapeutics Shares Are Trading Lower. The Company Reported Results From Its Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma.

Marker Therapeutics的股价走低。该公司报告了其针对复发性淋巴瘤的Mt-601的1期阿波罗研究结果。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发